Palo Alto, California 94305

  • Allogeneic Hematopoietic Cell Transplant Recipient


Chronic graft versus host disease (cGVHD) is a common complication of bone marrow or hematopoietic cell transplant from another person (allogeneic transplant). This study will determine if subjects with steroid dependent/refractory cGVHD can tolerate infusion of donor regulatory T cells and whether their cGVHD responds to the infusion.

Study summary:

PRIMARY OBJECTIVES: Determine the safety and tolerability of donor T regulatory (Treg) cell infusions in subjects with steroid dependent/refractory chronic graft versus host disease. SECONDARY OBJECTIVES: 1. Determine the quantitative blood Treg cell changes following the cell infusions 2. Determine clinical efficacy of donor Treg cells as failure-free survival (FFS) defined by the absence of a new immunosuppressive therapy added, non-relapse mortality, and recurrent malignancy at Day 180 after the first Treg infusion 3. In addition to FFS, the study will measure the change in: 1. cGVHD symptom burden measured by the Lee cGVHD Symptom Scale by increase in >7 points 2. NIH organ-specific cGVHD scale 3. The reduction in daily corticosteroid requirement of prednisone to <=0.25 mg/kg-day at Day 180 after the first Treg infusion


Inclusion Criteria: - Steroid dependent/refractory cGVHD defined as: - Steroid dependent disease: Persistent cGVHD manifestations requiring a glucocorticoid dose >= prednisone 0.25 mg/kg/day (0.5 mg/kg orally [po] every other day) for at least 12 weeks - Steroid refractory disease: Progressive cGVHD manifestations despite treatment with a glucocorticoid dose >= prednisone 0.5 mg/kg/day (1 mg/kg po every other day) for at least 4 weeks - Participants must be receiving systemic glucocorticoid therapy for cGVHD; all immunosuppressive therapy may include but not be limited to tacrolimus, sirolimus, CellCept, cyclosporine, and systemic corticosteroid must be at stable doses for 28 days prior to the first cell infusion - Chronic GVHD manifestations that can be followed on physical or laboratory exam; these include but are not necessarily limited to: - Skin changes - Oral mucosa changes - Bronchiolitis obliterans - Ocular changes - Karnofsky performance status >= 60 - Serum creatinine =< 2 mg/dL - Absolute neutrophil count (ANC) > 1 x 10^9/L - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 20 x upper limit of normal (ULN) or - Total bilirubin =< 10 x ULN - Allogeneic hematopoietic cell transplant recipient - Transfusion independent - Oxygen saturation during exertion is maintained at >= 88% on room air - Does not have clinically significant, symptomatic uncontrolled heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension) - DONOR: Age >= 18 to =< 75 years old - DONOR: Karnofsky performance status of >= 70% defined by institutional standards - DONOR: Must be the same sibling donor from whom the recipient's blood and marrow graft was collected for the original allogeneic transplant that is human leukocyte antigen (HLA) 7/8 or 8/8 matched at the HLA-A, B,C, DRB1 - DONOR: Serologies for human immunodeficiency virus (HIV) antigen (Ag), HIV 1 and HIV 2 antibody (Ab), human T-lymphotropic virus type I (HTLV 1) and HTLV 2 Ab, hepatitis B surface antigen (sAg) or polymerase chain reaction positive (PCR+), or hepatitis C Ab or PCR+, Syphilis (Treponema) screen and HIV 1 and hepatitis C by nucleic acid testing (NAT) have been collected prior to apheresis - DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within three weeks of apheresis - DONOR: Capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central catheter should leukapheresis via peripheral vein be inadequate - DONOR: Donor selection will be in compliance with 21 Code of Federal Regulations (CFR) 1271 Exclusion Criteria: - Original transplant utilized an unrelated donor graft - Uncontrolled infections that are not responsive to antimicrobial therapy - Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy - Second malignancy except for skin cancer within the last 5 years - Received any investigational agent =< 28 days before Treg infusions - Received filgrastim (GCSF) treatment within one month of enrollment - Received a donor lymphocyte infusion (DLI) or hematopoietic cell transplantation (HCT) within 3 months of enrollment - DONOR: Evidence of active infection or viral hepatitis - DONOR: HIV positive - DONOR: Pregnant donor



Primary Contact:

Joanne M Otani, RN, MSN, PHN
Phone: 650-721-2372

Backup Contact:


Location Contact:

Palo Alto, California 94305
United States

Joanne Otani, RN, MSN, PHN
Phone: 650-721-2372

Site Status: Recruiting

Data Source:

Date Processed: September 26, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.